Gefitinib

Recommended dose is 250 mg orally, once daily with or without food. 2.1 Patient Selection Select patients for the first-line treatment of metastatic NSCLC with gefitinib tablets based on the presence of EGFR exon 19 deletions or exon 21 L858R mutations in their tumor or plasma specimens. If these mutations are not detected in a plasma specimen, test tumor tissue if feasible.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Interstitial lung disease (ILD): ILD occurred in patients taking gefitinib tablets. Withhold gefitinib tablets for worsening of respiratory symptoms. Discontinue gefitinib tablets if ILD is confirmed.,Hepatotoxicity: Obtain periodic liver function testing. Withhold gefitinib tablets for Grade 2 or higher for ALT and/or AST elevations.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following adverse drug reactions are discussed in more detail in other sections of the labeling: Interstitial Lung Disease, Hepatotoxicity, Gastrointestinal Perforation, Severe or Persistent Diarrhea, Ocular Disorders including Keratitis, Bullous and Exfoliative Skin Disorders The most commonly reported adverse drug reactions (ADRs), reported in more than 20% of the patients and greater than placebo were skin reactions…

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

55 products from 53 makers in the NepalDoc medicine catalog use this generic:

Showing 30 of 55 catalog products. Search the full catalog in the app.

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Store at controlled room temperature 20°C-25°C (68°F-77°F).

Storage information from the U.S. FDA-approved label.